Related by context. All words. (Click for frequent words.) 67 relapsed MM 66 BARACLUDE ® 66 APTIVUS r 66 CANCIDAS 65 evaluable subjects 65 tipranavir r 64 RRMS patients 64 protease inhibitor PI 64 mg/m2 dose 64 dose cohorts 63 SCIg 63 COPAXONE R 63 APTIVUS 63 BENICAR HCT 63 ruboxistaurin 63 TMC# r 63 GSK# [001] 63 MERLIN TIMI 63 PREZISTA r 63 ABSORB trial 62 CIMZIA ™ 62 Betaferon R 62 paricalcitol 62 INTELENCE 62 virologic failure 62 dosing cohort 62 EMPHASIS HF trial 62 viral kinetics 62 genotypic resistance 62 heavily pretreated 62 dose cohort 62 MADRS score 62 CIMZIA TM 61 HBeAg negative patients 61 HER2 positive metastatic breast 61 cART 61 Pharmacokinetic parameters 61 anemia hemoglobin 61 LEXIVA r 61 serum urate levels 61 teriflunomide 61 ritonavir boosted lopinavir 61 mg kg dose 61 MCyR 61 fluvastatin 61 CHAMPION PCI 61 relapsing MS 61 EURIDIS 61 hepatitis C genotype 61 PreCISe study 61 infliximab therapy 61 lacosamide 61 placebo controlled clinical trials 61 dose escalation phase 61 HBeAg positive 61 NATRECOR R 61 MoxDuo TM IR 61 salmeterol fluticasone 60 tocilizumab 60 mg BID dose 60 prospectively defined 60 hematologic toxicity 60 YONDELIS 60 fosamprenavir 60 HBeAg seroconversion 60 Subgroup analysis 60 riociguat 60 undetectable HBV DNA 60 APTIVUS R 60 HCV RESPOND 2 60 antiretroviral naïve 60 antiretroviral naive 60 Dose escalation 60 desvenlafaxine succinate 60 CIMZIA TM certolizumab pegol 60 FOLFIRINOX 60 PASI scores 60 efavirenz EFV 60 null responder HCV 60 lumiliximab 60 antihypertensive therapy 60 #mg/day [001] 60 mg BID 60 LUMINATE 60 Crohn Disease Activity 60 KRAS status 60 solifenacin 60 vicriviroc 60 irbesartan 60 MAGE A3 ASCI 60 recurrent glioblastoma multiforme 60 refractory CLL 60 Betaferon ® 60 Amrubicin 60 bendamustine 60 BENICAR 60 entecavir 60 canakinumab 60 DMARD therapy 59 RSD# oral 59 INC# 59 REMICADE ® 59 phase IIb trial 59 interferon beta therapy 59 oxycodone CR 59 double blinded placebo 59 gadobutrol 59 DAS# CRP 59 diuretic chlorthalidone 59 HBeAg 59 INCB# [003] 59 PSMA ADC 59 recurrent glioma 59 NAbs 59 low dose cytarabine 59 fosbretabulin 59 elotuzumab 59 CCyR 59 elevated ALT 59 randomized multicenter trial 59 HCV SPRINT 59 β blockers 59 brivaracetam 59 Subgroup analyzes 59 pegylated interferon alpha 59 ALT flares 59 blinded randomized placebo controlled 59 docetaxel chemotherapy 59 HBeAg negative 59 prucalopride 59 secondary efficacy endpoints 59 hematologic parameters 59 peginterferon 59 interferon alfa 59 baseline HbA1c 59 Phase 2a trial 59 PegIFN RBV 59 ORENCIA ® 59 lipid lowering agents 59 oral FTY# 59 heavily pretreated patients 59 virologic response EVR 59 receiving VICTRELIS 59 PRECiSE 59 mcg albinterferon alfa 2b 59 virologic response 59 nondiabetic patients 59 dacetuzumab 59 ONGLYZA saxagliptin 59 adalimumab 59 ALT elevations 59 refractory AML 59 phase Ib 59 serologically active patients 59 pomalidomide 59 ascending dose 59 aspartate aminotransferase AST 59 receiving golimumab 59 tigecycline 59 glycated hemoglobin levels 59 Traficet EN 59 serum HCV RNA 59 rizatriptan 58 standard chemotherapy regimen 58 INCB# [001] 58 IFN beta 58 ULORIC 58 ZOLINZA 58 ancrod 58 Dasatinib 58 insulin detemir 58 LTBI 58 doxorubicin docetaxel 58 superficial bladder cancer 58 IRESSA 58 cinacalcet 58 macroalbuminuria 58 bortezomib refractory 58 dosing cohorts 58 ACTEMRA TM 58 ritonavir boosted 58 VADT 58 complete cytogenetic response 58 EDSS score 58 HbA 1c levels 58 ACR# responses 58 rosuvastatin #mg 58 trastuzumab Herceptin ® 58 Hb A1C 58 Engerix B 58 ToGA 58 timepoint 58 ELOXATIN 58 pegylated interferon alfa 2b 58 virological failure 58 Teriflunomide 58 endoscopic remission 58 transaminase elevations 58 COPAXONE ® 58 non squamous NSCLC 58 KRAS mutations occur 58 timepoints 58 trials RCTs 58 dasatinib 58 HSCT 58 imatinib therapy 58 AGILECT R 58 OPT CHF 58 LIALDA 58 GOUT 58 VaD 58 NATRECOR ® 58 aminotransferases 58 antiangiogenic therapy 58 BEXXAR 58 lupus nephritis 58 stage IIIB 58 EOquin 58 HCV infected 58 serum phosphorous 58 elevated serum creatinine 58 regorafenib 58 #mg BID [002] 58 rFVIIa 58 tipranavir 58 NNRTI resistance 58 anticholinergics 58 mapatumumab 58 splenectomized patients 58 daunorubicin 58 ACZ# 58 eplerenone 58 metastatic HRPC 58 STELARA 58 Index CDAI 58 ximelagatran 58 efficacy endpoint 58 R# #mg BID 58 ARIXTRA 58 inhibitor RG# 58 MabCampath 58 lipid lowering therapy 58 severe exacerbations 58 octreotide LAR 58 liver transplant recipients 58 histologically confirmed 58 doxorubicin cyclophosphamide 58 MGd 58 hypertensives 58 null responder 58 mcg BID 58 plus methotrexate 58 sunitinib 58 dyslipidaemia 58 Virologic failure 58 glatiramer acetate 58 subanalysis 58 HBeAg positive patients 58 HIV uninfected 58 gemcitabine carboplatin 58 hemoglobin A1c HbA1c 58 budesonide foam 58 atazanavir ritonavir 58 Ceplene/IL-2 58 placebo dexamethasone 58 FOLPI 58 darunavir ritonavir 58 highly emetogenic 58 ENESTnd 58 undetectable HCV RNA 58 visilizumab 58 infliximab 58 evaluable patients 58 forodesine 58 serum urate 57 tanespimycin 57 LY# [003] 57 HuMax EGFr 57 RE LY ® 57 metastatic RCC 57 BAY #-# 57 Response Evaluation Criteria 57 HER2 overexpression 57 HIV RNA 57 REYATAZ r arm 57 cabazitaxel 57 Tarceva TM 57 placebo controlled trials 57 achieved CCyR 57 mg ustekinumab 57 visceral metastases 57 chlorambucil 57 abiraterone acetate 57 cytologically confirmed 57 ribavirin RBV 57 log# reduction 57 NO# [002] 57 peginterferon alfa 2a 57 Psoriasis Area 57 certolizumab 57 ABC/3TC 57 levosimendan 57 plasma pharmacokinetics 57 bezafibrate 57 Celsentri Selzentry 57 FDA defined valvulopathy 57 CALGB 57 HQK 57 specific antigen PSA 57 Secondary efficacy endpoints 57 STRIDE PD 57 HORIZONS AMI trial 57 AIR CF1 57 mycophenolate mofetil 57 adalimumab Humira 57 crizotinib PF # 57 ibandronate 57 citalopram 57 mRCC 57 alicaforsen enema 57 alemtuzumab treated 57 titrated glipizide 57 phase IIa clinical 57 ENGAGE AF TIMI 57 Primary endpoints 57 CCR5 tropic HIV 57 systemic ALCL 57 ACR# ACR# 57 ertapenem 57 posaconazole 57 atherogenic dyslipidemia 57 ACR# response 57 active comparator 57 DOXIL 57 metastatic renal cell carcinoma 57 serum uric acid 57 CAMMS# 57 CLARITY study 57 MAS XR 57 clinically meaningful improvement 57 lopinavir r arm 57 vandetanib 57 cytoreductive nephrectomy 57 rilonacept 57 PRADAXA 57 HIV HCV coinfected 57 antiviral efficacy 57 differentiated thyroid 57 zonisamide SR 57 posttreatment 57 mg/m2 cohort 57 VELCADE melphalan 57 T2DM 57 IV NSCLC 57 vismodegib 57 postintervention 57 symptomatic VTE 57 CHOP chemotherapy 57 divalproex sodium 57 EDSS scores 57 FluCAM arm 57 coinfected patients 57 sustained virological response 57 pertuzumab 57 uric acid lowering 57 ziconotide 57 Flu Cy 57 GnRH agonists 57 tacrolimus ointment 57 Dapagliflozin 57 ß blockers 57 lamivudine refractory patients 57 preoperative chemotherapy 57 placebo controlled clinical 57 grade cervical intraepithelial 57 micafungin 57 DAPT 57 xanthine oxidase inhibitor 57 mITT population 57 AEGR 57 talabostat 57 PEG IFN 57 blood phenylalanine Phe 57 selective modulator 57 dose cytarabine 57 lipid lowering drugs 57 metastatic CRC 57 GAMMAGARD 57 mcg QD 56 experienced virologic failure 56 placebo controlled Phase 56 Doxil ® 56 subgroup analyzes 56 rapid virologic response 56 TEAEs 56 Ozarelix 56 REYATAZ ® 56 Pemetrexed 56 RECIST Response Evaluation Criteria 56 briakinumab 56 #mg dose [003] 56 unfractionated heparin UFH 56 ZD# [001] 56 dosage regimens 56 ZACTIMA 56 Omacetaxine 56 liver histology 56 potent antiretroviral therapy 56 Tyrima 56 somatostatin analog 56 nitazoxanide 56 definite stent thrombosis 56 TAXUS Stent 56 ZYVOX 56 Scale EDSS 56 Serdolect ® 56 corticosteroid dose 56 azacitidine 56 dexamethasone Decadron 56 peginterferon alfa 56 achieved sustained virological 56 beta blocker therapy 56 serum HBV DNA 56 ADAGIO study 56 alvespimycin 56 ACR Pedi 56 AIM HIGH 56 #mg dose [002] 56 HPV-#/# 56 8mg/kg 56 denosumab oncology clinical trials 56 candesartan 56 fasting triglyceride levels 56 iniparib 56 dacarbazine chemotherapy 56 tuberculin skin testing 56 BRIM2 56 postoperative chemotherapy 56 flutamide 56 sustained virologic response 56 TNF alpha inhibitor 56 galiximab 56 rimonabant #mg 56 Screening Trial DMIST 56 stable angina 56 PREZISTA r arm 56 CR nPR 56 adjuvant tamoxifen 56 inflammatory biomarkers 56 phase IIa 56 serum phosphate 56 clinical pharmacology studies 56 relapsing multiple sclerosis 56 PEGINTRON TM 56 PLCO 56 placebo controlled studies 56 recurrent GBM 56 angiographic outcomes 56 sulfasalazine 56 Reverset 56 YERVOY 56 Phase IIIb clinical 56 axitinib 56 biologic DMARD 56 pramlintide 56 mg dose 56 mg RDEA# 56 XELOX 56 tolvaptan 56 dysglycemia 56 fluoxetine paroxetine 56 zolmitriptan 56 nonmetastatic prostate cancer 56 CONCERTA ® 56 prospective randomized multicenter 56 PROactive study 56 achieved PASI 56 diabetic neuropathic pain 56 Phase 1b trial 56 Zevalin consolidation 56 EDEMA3 56 adjunctive placebo 56 concomitant medications 56 multicenter randomized controlled 56 USL# 56 Hepatotoxicity 56 evaluating tivozanib 56 PROSTVAC ® 56 metastatic CRPC 56 peg interferon 56 ponatinib 56 Pegasys ® 56 attain statistical significance 56 tapentadol ER 56 icatibant 56 DLTs 56 GnRH agonist 56 q#h 56 pyrazinamide 56 Pegasys peginterferon alfa 2a 56 NIH CPSI 56 DMARD 56 vidofludimus 56 sunitinib malate 56 overt nephropathy 56 adefovir 56 Tipranavir 56 dalteparin 56 peg IFN 56 Secondary endpoints 56 lesinurad 56 EQUIP OB 56 FluCAM 56 monoamine oxidase inhibitors MAOIs 56 poor metabolizers 56 follicular lymphoma FL 56 risperidone olanzapine 56 BRIM3 56 caspofungin 56 Aptivus ® 56 #mg BID [001] 56 RAPAFLO R 56 receptor tyrosine kinase inhibitor 56 Durezol 56 dose proportionality 56 ZOMIG Nasal Spray 56 XIENCE V PROMUS Stent 56 azilsartan medoxomil 56 leukemia AML 56 achieved ACR# 56 Ophena TM 56 viral kinetic 56 stage IIIB IV 56 AIR CF3 56 PEGylated interferon beta 1a 56 HPTN 56 patients evaluable 56 nilotinib 56 ABSSSI 56 cTnT levels 56 NRTI 56 Phase Ib study 56 dopamine partial agonist 56 pCR 56 mcg dose 56 Xanafide 56 metastatic hormone refractory 56 mucosal healing 56 dapagliflozin plus 56 decitabine 56 analgesic efficacy 56 ARB telmisartan 56 ALVESCO 56 tipranavir ritonavir 56 blood Phe 56 #mg doses [002] 56 Capacity FVC 56 elevated LDL cholesterol 56 Baseline characteristics 56 APTIVUS ritonavir 56 achieving PASI 56 antihypertensive medications 56 sorafenib tablets 56 pharmacodynamic PD 55 venlafaxine XR 55 logistic regression models 55 moderate renal impairment 55 eosinophilic asthma 55 cilengitide 55 sevelamer 55 strontium ranelate 55 abatacept 55 CTEPH 55 RE LY 55 serum IGF 55 EOquin TM phase 55 double blinded randomized 55 blood Phe levels 55 perioperatively 55 phase IIb study 55 methotrexate therapy 55 goserelin 55 olmesartan 55 exploratory endpoints 55 CLL SLL 55 RoACTEMRA 55 castration resistant prostate cancer 55 morphometric vertebral fractures 55 Azilect ® 55 REMINYL ® 55 relapsed multiple myeloma 55 TMC# C# 55 suboptimal adherence 55 baseline PASI 55 pramlintide metreleptin combination 55 efalizumab 55 EOquin TM 55 virological response 55 RE LY trial 55 Tanespimycin 55 cediranib 55 multicenter multinational 55 neratinib 55 HGS# 55 HCV genotype 1 55 squamous histology 55 PRE SURGE 55 ARCOXIA 55 Paxil paroxetine 55 DEB# 55 ALLHAT 55 pharmacodynamic 55 Severity Index PASI 55 acute gout flares 55 HbA 1c 55 mCRC patients 55 Phase 2b trial 55 Phase Ib II 55 nonvertebral fractures 55 NYHA functional class 55 relapsed refractory multiple myeloma 55 multicenter randomized placebo controlled 55 Brief Psychiatric 55 QTc prolongation 55 SSRI SNRI 55 maximally tolerated dose 55 cells mcL 55 FOSRENOL ® 55 NYHA Class II 55 Kaplan Meier analysis 55 fasting plasma glucose FPG 55 platinum refractory 55 alanine aminotransferase ALT 55 HbA1c levels 55 anagrelide 55 randomized Phase IIb 55 Elitek 55 untreated AML 55 antihypertensive agents 55 glatiramer acetate Copaxone 55 doripenem 55 peginterferon alfa 2b 55 acute coronary syndromes ACS 55 limiting toxicity 55 metformin monotherapy 55 sUA 55 virologic 55 infusional 5-FU/LV 55 advanced adenoma 55 serum parathyroid hormone 55 virologic breakthrough 55 lanthanum carbonate 55 Taxotere ® 55 squamous cell histology 55 Golimumab 55 antidepressant therapy 55 MYLOTARG 55 oral anticoagulation 55 CDAI 55 anti leukemic 55 hours postdose 55 advanced adenomas 55 ara C 55 colesevelam HCl 55 NYHA Class III 55 Non inferiority 55 symptomatic BPH 55 UKPDS 55 DAS# scores 55 retrospective cohort 55 MADIT CRT trial 55 mg QD 55 Afatinib 55 hyperphenylalaninemia HPA due 55 cEVR 55 Velcade bortezomib 55 lamotrigine 55 BEXXAR Therapeutic Regimen 55 phase IIb clinical 55 Darusentan 55 SPRYCEL ® 55 nab paclitaxel 55 Enzastaurin 55 glycated hemoglobin HbA1c 55 trastuzumab emtansine T DM1 55 COMBIVIR 55 TNF antagonist 55 COMFORT II 55 rHuPH# 55 hemagglutination inhibition 55 risperidone Risperdal 55 Acute Decompensated Heart Failure 55 Adalimumab 55 thrombocytopenic 55 Vectibix monotherapy 55 L PPDS 55 serum retinol 55 prospective randomized placebo 55 citalopram hydrobromide 55 idraparinux 55 logistic regression analysis 55 romiplostim 55 PREZISTA ritonavir 55 annualized relapse 55 NHANES III 55 mITT 55 abacavir Ziagen 55 recurrent NSCLC 55 paclitaxel cisplatin 55 serum phosphate levels 55 venlafaxine ER 55 refractory multiple myeloma 55 prior chemotherapy regimens 55 AVONEX ® 55 enzastaurin 55 maximal doses 55 HGPIN 55 treatment naïve genotype 55 mCi kg 55 thiopurine 55 Welchol 55 platelet reactivity 55 5-FU/LV 55 BMS # 55 APEX PD 55 seroprotection 55 COPD exacerbation 55 adjuvant trastuzumab 55 Aflibercept 55 operable pancreatic cancer 55 completely resected 55 alpha 2a 55 mg Proellex 55 prostate cancer HRPC 55 umol L 55 tarenflurbil 55 BEACOPP 55 LymphoStat B 55 Phase IIIb 55 recurrent endometrial cancer 55 6R BH4 55 pramipexole 55 abacavir lamivudine 55 Cariprazine 55 fluticasone salmeterol 55 Solid Tumours 55 HER2 positive cancers 55 Gleevec imatinib 55 migalastat HCl 55 alefacept 55 CHAMPION PLATFORM 55 imatinib mesylate 55 malignant pleural mesothelioma 55 statistical significance p 55 trastuzumab DM1 55 Bezielle 55 pharmacokinetic PK profile 55 PEG Interferon lambda 55 Dacogen decitabine 54 epoetin beta 54 hemoglobin A1c levels 54 estimated GFR 54 randomized controlled trials RCTs 54 Degarelix 54 LibiGel Phase III 54 interferon alfa 2b 54 aflibercept 54 ATACAND 54 celgosivir 54 efficacy evaluable 54 TACI Ig 54 Mipomersen 54 dacarbazine DTIC 54 vinorelbine 54 iniparib BSI 54 temsirolimus 54 sargramostim 54 candesartan cilexetil 54 lopinavir r 54 octreotide 54 seroconverted 54 Copegus ribavirin 54 Interferon beta 1b 54 aprepitant 54 RTOG 54 concurrent chemoradiation 54 treatment naive genotype 54 dose regimens 54 lipid lowering medications 54 gefitinib 54 Swedish Mammography Cohort 54 peginterferon alfa 2a #KD 54 bortezomib 54 refractory cutaneous T 54 Natalizumab 54 bortezomib Velcade 54 #mg/day [002] 54 recurrent genital herpes 54 mitoxantrone plus 54 thorough QT 54 Phase Ib clinical 54 BARI 2D 54 baseline LDH 54 SSRI citalopram 54 multivariate analyzes 54 pregabalin 54 sorafenib Nexavar 54 pegylated interferon alfa 2a 54 REVIVE Diabetes 54 boosted protease inhibitor 54 hematopoietic cancers 54 phase IIb 54 NIHSS 54 dabigatran etexilate 54 plus dexamethasone 54 pharmacokinetic interactions 54 ziprasidone 54 EchoCRT 54 HER2 expression 54 observational cohort 54 HUMIRA adalimumab 54 Phase IIIb study 54 taxane refractory 54 etanercept 54 Tolvaptan 54 refractory indolent non 54 Lamotrigine 54 ALT normalization 54 stavudine 54 GW# [003] 54 LUX Lung 54 nonpregnant women 54 sorafenib Nexavar ® 54 phase IIIb 54 schizophrenia CIAS 54 refractory NSCLC 54 Roche Xeloda 54 RhuDex ® 54 Sapacitabine 54 stage IIIb IV 54 null responders 54 BROVANA 54 eszopiclone 54 pegylated alpha interferon 54 apremilast 54 K ras mutations 54 IV metastatic melanoma 54 HBeAg negative chronic hepatitis 54 PsA 54 BR.# 54 systolic dysfunction 54 serum lipid levels 54 LPV r 54 biochemical relapse 54 voriconazole 54 Rilonacept 54 IFN α 54 Plicera 54 anthracyclines taxanes 54 neoadjuvant 54 Mitoxantrone 54 intravenous bisphosphonates 54 adenoma recurrence 54 AVADO 54 PRoFESS 54 complete cytogenetic 54 carboplatin paclitaxel 54 VFEND 54 pharmacokinetics PK 54 genotype 1a 54 #mg/m# [002] 54 Kinoid 54 elevated triglyceride levels 54 COU AA 54 glomerular filtration 54 ANCHOR trial 54 Femara letrozole 54 pharmacokinetic PK 54 mGluR5 NAM 54 inflammatory lesions 54 plus OBT 54 antiepileptics 54 CYT# potent vascular disrupting 54 Dabigatran etexilate 54 hypertensive patients 54 neoadjuvant chemotherapy 54 spirometric 54 registrational trial 54 invasive aspergillosis 54 Study GL# 54 CVD mortality 54 cytogenetic response 54 Health Initiative Observational 54 taxane therapy 54 FAME Study 54 NOXAFIL 54 comparator PI r 54 DAS# remission 54 urate lowering therapy 54 atherothrombotic disease 54 CTAP# Capsules 54 vildagliptin 54 Tocilizumab 54 intravenous diuretics 54 non metastatic osteosarcoma 54 amoxicillin clavulanate 54 plus ribavirin 54 HGS ETR1 54 response CCyR 54 haloperidol Haldol 54 ribavirin therapy 54 evaluating REVLIMID 54 multicentre randomized 54 Toxicities 54 omalizumab 54 serum leptin 54 serum phosphorus 54 urinary N telopeptide 54 μmol L 54 cell lymphoma CTCL 54 antiarrhythmic drug 54 Blinatumomab 54 CLL8 54 dose limiting toxicities 54 p# biomarker 54 desvenlafaxine 54 oral rivaroxaban 54 relapsing remitting MS RRMS 54 dose titration 54 ACCORD Lipid 54 Raptiva r 54 invasive candidiasis 54 Hematologic 54 resectable 54 mcg doses 54 psoriatic arthritis PsA 54 estramustine 54 CIN3 54 nonrandomized 54 Jevtana 54 detectable HCV RNA 54 teduglutide 54 prostate cancer CaP 54 CONQUER OB 54 chemotherapy regimen 54 atypical Hemolytic Uremic Syndrome 54 Pertuzumab 54 TAXUS VI 54 randomized multicenter 54 monotherapy 54 MAP# 54 pimozide 54 seropositive patients 54 ICD therapy 54 CYPHER Stent 54 ISEL 54 multicenter Phase III 54 4mg/kg 54 serum calcium 54 serum uric acid sUA 54 latent tuberculosis infection 54 pegylated interferon alfa 54 aripiprazole Abilify 54 placebo controlled Phase III 54 nicardipine 54 NeuroStar TMS Therapy 54 events SAEs 54 reboxetine 54 Onbrez Breezhaler 54 euthymic patients 54 lenalidomide Revlimid R 54 CCR5 receptor antagonist 54 LV dysfunction 54 pegylated liposomal doxorubicin 54 T#I [002] 54 EndoTAG TM -1 54 Cloretazine 54 adecatumumab 54 CytoFabTM 54 #mg QD [001] 54 prospective multicentre 54 ADVANCE PD 54 oral diclofenac 54 docetaxel 54 -#.# log# 54 mild renal insufficiency 54 gastrointestinal stromal tumors GIST 54 prospective observational 54 neuroleptic 54 HbA1C levels 54 bladder carcinoma 54 mildly symptomatic 54 OLYMPIA registry 54 IV bisphosphonates 53 Framingham Offspring Study 53 NSTE ACS 53 CRESTOR #mg 53 intravenous dosing 53 chronic periodontitis